Cited 43 times in
Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신성재 | - |
dc.date.accessioned | 2017-10-26T07:56:11Z | - |
dc.date.available | 2017-10-26T07:56:11Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152708 | - |
dc.description.abstract | Macrolides, such as azithromycin (AZM) and clarithromycin, are the cornerstones of treatment for Mycobacterium avium complex lung disease (MAC-LD). Current guidelines recommend daily therapy with AZM for cavitary MAC-LD and intermittent therapy for noncavitary MAC-LD, but the effectiveness of these regimens has not been thoroughly investigated. This study evaluated associations between microbiological response and estimated peak plasma concentrations (Cmax) of AZM. The AZM Cmax was measured in patients receiving daily therapy (250 mg of AZM daily, n = 77) or intermittent therapy (500 mg of AZM three times weekly, n = 89) for MAC-LD and daily therapy for Mycobacterium abscessus complex LD (MABC-LD) (250 mg of AZM daily, n = 55). The AZM Cmax was lower with the daily regimen for MAC-LD (median, 0.24 μg/ml) than with the intermittent regimen for MAC-LD (median, 0.65 μg/ml; P < 0.001) or daily therapy for MABC-LD (median, 0.53 μg/ml; P < 0.001). After adjusting for confounding factors, AZM Cmax was independently associated with favorable microbiological responses in MAC-LD patients receiving a daily regimen (adjusted odds ratio [aOR], 1.58; 95% confidence interval [CI], 1.01 to 2.48; P = 0.044) but not an intermittent regimen (aOR, 0.85; 95% CI, 0.58 to 1.23, P = 0.379). With the daily AZM-based multidrug regimen for MAC-LD, a low AZM Cmax was common, whereas a higher AZM Cmax was associated with favorable microbiologic responses. The results also suggested that the addition of rifampin may lower AZM Cmax When a daily AZM-based multidrug regimen is used for treating severe MAC-LD, such as cavitary disease, the currently recommended AZM dose might be suboptimal. (This study has been registered at ClinicalTrials.gov under identifier NCT00970801.). | - |
dc.description.statementOfResponsibility | open | - |
dc.publisher | American Society for Microbiology | - |
dc.relation.isPartOf | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anti-Bacterial Agents/blood | - |
dc.subject.MESH | Anti-Bacterial Agents/pharmacokinetics* | - |
dc.subject.MESH | Area Under Curve | - |
dc.subject.MESH | Azithromycin/blood | - |
dc.subject.MESH | Azithromycin/pharmacokinetics* | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Ethambutol/blood | - |
dc.subject.MESH | Ethambutol/pharmacokinetics* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung/drug effects | - |
dc.subject.MESH | Lung/microbiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Models, Statistical* | - |
dc.subject.MESH | Mycobacterium avium Complex/drug effects | - |
dc.subject.MESH | Mycobacterium avium Complex/growth & development | - |
dc.subject.MESH | Mycobacterium avium-intracellulare Infection/blood | - |
dc.subject.MESH | Mycobacterium avium-intracellulare Infection/drug therapy* | - |
dc.subject.MESH | Mycobacterium avium-intracellulare Infection/microbiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Rifampin/blood | - |
dc.subject.MESH | Rifampin/pharmacokinetics* | - |
dc.subject.MESH | Sputum/microbiology | - |
dc.title | Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Microbiology | - |
dc.contributor.googleauthor | Byeong-Ho Jeong | - |
dc.contributor.googleauthor | Kyeongman Jeon | - |
dc.contributor.googleauthor | Hye Yun Park | - |
dc.contributor.googleauthor | Seong Mi Moon | - |
dc.contributor.googleauthor | Su-Young Kim | - |
dc.contributor.googleauthor | Soo-Youn Lee | - |
dc.contributor.googleauthor | Sung Jae Shin | - |
dc.contributor.googleauthor | Charles L. Daley | - |
dc.contributor.googleauthor | Won-Jung Koh | - |
dc.identifier.doi | 10.1128/AAC.00770-16 | - |
dc.contributor.localId | A02114 | - |
dc.relation.journalcode | J00189 | - |
dc.identifier.eissn | 1098-6596 | - |
dc.identifier.pmid | 27480854 | - |
dc.contributor.alternativeName | Shin, Sung Jae | - |
dc.contributor.affiliatedAuthor | Shin, Sung Jae | - |
dc.citation.volume | 60 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 6076 | - |
dc.citation.endPage | 6083 | - |
dc.identifier.bibliographicCitation | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Vol.60(10) : 6076-6083, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 39717 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.